NGeneBio said it agreed with Agilent Technologies Korea, a global gene analysis equipment company, to cooperate in the Korean and international next-generation sequencing (NGS) precision diagnostics market.

NGS-based precision diagnosis of cancer, which tests multiple genes simultaneously, is a critical technology for precision medicine. It can enhance treatment prognosis by providing personalized targeted therapies that are tailored to each patient's specific needs.

Nevertheless, conducting such tests in clinical settings presents significant challenges due to the complexity of experiments and the difficulty in analyzing genomic data.

Under the latest agreement, NGeneBio's solid cancer precision diagnostic product, ONCOaccuPanel will be applied to Agilent's Magnis NGS Prep System. Then, Agilent can sell it as a package.

Agilent's Magnis NGS Prep System is an automated device that can easily and quickly perform complex NGS tests in clinical settings. 

"By combining NGeneBio's genomic data analysis solutions with Agilent's automation systems, we can help accelerate the adoption of NGS testing by addressing the complexity of NGS experimental steps and analytical challenges," NGenBio CEO Choi Dae-chul said. "The synergies of this agreement will strengthen our competitiveness in the NGS precision medicine market."